Immuron licenses Travelan in China region
Immuron (ASX:IMC) has signed an agreement with a Chinese distributor to sell its Travelan OTC preventative treatment for traveller’s diarrhoea in China, Hong Kong and Macau.
Linker Holdings has negotiated the exclusive rights to market, sell and distribute Travelan in the region as a functional food and dietary supplement.
The agreement is contingent on Linker securing regulatory approval from the Chinese Food and Drug Administration.
Immuron said Linker has agreed to comply with annual minimum purchase obligations, and even these obligations represent a significant increase in Travelan sales figures, to the extent that it’s measurable in multiples of current volumes.
Immuron chairman Dr Roger Aston said Travelan is currently available in Australia and Canada, but the Chinese market has the potential to eclipse both markets combined in terms of demand.
“China is a large and increasingly wealthy market, in which gut and liver health are important concerns,” he said. “Additionally, the South East Asian cultures’ predisposition to, and appreciation of, the benefits of colostrum strongly positions Travelan in this market.”
Colostrum is the first milk produced by a pregnant mammal - it is naturally rich in antibodies. Immuron derives Travelan from cows that have been immunised with a proprietary vaccine against enterotoxigenic escherichia coli (ETEC).
Immuron (ASX:IMC) shares were trading 12.2% higher at $0.23 as of around 1 pm on Tuesday.
Aspirin could prevent some cancers from spreading
The research could lead to the targeted use of aspirin to prevent the spread of susceptible types...
Heat-induced heart disease is killing Australians
Hot weather is responsible for an average of almost 50,000 years of healthy life lost to...
Call for greater diversity in genomics research
A gene variant common in Oceanian communities has been misclassified as a potential cause of...
